JPWO2023048231A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023048231A5
JPWO2023048231A5 JP2023549745A JP2023549745A JPWO2023048231A5 JP WO2023048231 A5 JPWO2023048231 A5 JP WO2023048231A5 JP 2023549745 A JP2023549745 A JP 2023549745A JP 2023549745 A JP2023549745 A JP 2023549745A JP WO2023048231 A5 JPWO2023048231 A5 JP WO2023048231A5
Authority
JP
Japan
Prior art keywords
cancer
sodium
verteporfin
tumor cells
talaporfin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549745A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023048231A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/035376 external-priority patent/WO2023048231A1/ja
Publication of JPWO2023048231A1 publication Critical patent/JPWO2023048231A1/ja
Publication of JPWO2023048231A5 publication Critical patent/JPWO2023048231A5/ja
Pending legal-status Critical Current

Links

JP2023549745A 2021-09-24 2022-09-22 Pending JPWO2023048231A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021155009 2021-09-24
PCT/JP2022/035376 WO2023048231A1 (ja) 2021-09-24 2022-09-22 腫瘍細胞を死滅させるための医薬

Publications (2)

Publication Number Publication Date
JPWO2023048231A1 JPWO2023048231A1 (https=) 2023-03-30
JPWO2023048231A5 true JPWO2023048231A5 (https=) 2025-05-26

Family

ID=85720780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549745A Pending JPWO2023048231A1 (https=) 2021-09-24 2022-09-22

Country Status (5)

Country Link
US (1) US20250000998A1 (https=)
EP (1) EP4406556A1 (https=)
JP (1) JPWO2023048231A1 (https=)
CN (1) CN117999098A (https=)
WO (1) WO2023048231A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230135752A1 (en) * 2020-03-27 2023-05-04 PhotoQ3 Inc. Medicament for killing tumor cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20200147233A1 (en) * 2018-10-09 2020-05-14 PhotoQ3 Inc. Method for killing tumor cells and composition used therefor

Similar Documents

Publication Publication Date Title
Eskander et al. Targeting angiogenesis in advanced cervical cancer
Ho et al. An overview of the rare parotid gland cancer
JP2012502938A5 (https=)
JPWO2023048231A5 (https=)
TW202537643A (zh) 抗體-藥物結合物之用途
JP2021511372A5 (https=)
Yu et al. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
US20230242554A1 (en) Photosensitizing dye
MX2025005779A (es) Conjugado de anticuerpo-farmaco, metodo de preparacion y uso del mismo
GEAP202416383A (en) Use of medicament in treatment of tumor disease
Atwell et al. Nuclear epidermal growth factor receptor as a therapeutic target
JPWO2021193928A5 (https=)
JP2025509564A5 (https=)
JP7329288B2 (ja) 腫瘍細胞を死滅させるための医薬
JP7769386B2 (ja) 腫瘍細胞を死滅させるための医薬
US20250000998A1 (en) Medicament for killing tumor cells
US20200147233A1 (en) Method for killing tumor cells and composition used therefor
Halani et al. “New targets in non–small-cell lung cancer”—RET, HER2, and KRAS
Hoy Trastuzumab Rezetecan: First Approval
CA3100422A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
Williams H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~ DeBakey Clinical Medical Research Award
JP2024528081A5 (https=)
Schardt et al. HER3-targeted affibodies with optimized formats reduce ovarian cancer progression in a mouse xenograft model
Li et al. 3H-3000, an FGFR2B-specific monoclonal antibody, shows superior tumor killing in vivo
Zhang et al. Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer